The FDA Approves a New Diagnostic Imaging Agent (Axumin) to Detect Recurrent Prostate Cancer.

Several positron emission tomography (PET) scans (including C-11 choline and acetate PET scans) exist whose purpose is to detect the location of recurrent prostate cancer when the PSA is at low levels. Within the last few days, the U.S. Food and Drug Administration approved another scan using an injected radioactive agent called Axumin. The following link from the FDA provides additional information concerning the reliability of the new scan and its comparison with existing PET scan reagents. Axumin is marketed by Blue Earth Diagnostics, Ltd., Oxford, United Kingdom.